IDEAYA Biosciences (IDYA) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tyler Van Buren’s rating is based on IDEAYA Biosciences’ promising pipeline, which includes nine clinical-stage programs focused on targeted oncology. The company’s lead asset, darovasertib, is particularly noteworthy due to its potential to address significant unmet needs in metastatic uveal melanoma (mUM) and neoadjuvant uveal melanoma (UM). The combination of darovasertib and crizotinib has shown impressive Phase II results, with a median progression-free survival of 7.1 months, which is significantly better than the current standard of care. This success reduces the risk associated with the upcoming pivotal Phase II/III trials.
Additionally, IDEAYA’s focus on synthetic lethality to target tumor vulnerabilities enhances its innovative approach. The upcoming data for IDE849, a DLL3-targeting ADC, is expected to demonstrate a wider therapeutic window, further supporting the company’s robust pipeline. With no approved treatments in the neoadjuvant setting, darovasertib has the potential to dominate this market, and IDEAYA’s strategic focus on unmet needs positions it well for future growth. These factors contribute to Van Buren’s Buy rating for IDEAYA Biosciences.
In another report released on July 9, RBC Capital also maintained a Buy rating on the stock with a $30.00 price target.